Company: ICUI
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0000883984-25-000035
Chunk: 144

Company: ICU MEDICAL INC/DE
Filing Date: 2025-11-06
Form: 10-Q
Item: Item 8
Chunk 144
---
 liabilities2,384 — 2,384 — Total Liabilities$3,672 $— $3,672 $—  Fair value measurements as of December 31, 2024 Total carryingvalueQuoted pricesin activemarkets foridenticalassets (level 1)Significantotherobservableinputs (level 2)Significantunobservableinputs (level 3)Assets:Foreign exchange contracts:Prepaid expenses and other current assets$6,716 $— $6,716 $— Interest rate contracts:Prepaid expenses and other current assets11,038 — 11,038 — Other assets5,724 — 5,724 — Total Assets$23,478 $— $23,478 $— Liabilities:Foreign exchange contracts:Accrued liabilities$7,391 $— $7,391 $— Total Liabilities$7,391 $— $7,391 $— Nonrecurring Fair Value MeasurementsWe measure certain items on a nonrecurring basis due to particular circumstances or when specific transactions occur such as a retained investment resulting from a partial sale. On May 1, 2025, we measured our retained equity method investment in Otsuka ICU Medical LLC (see Note 11: Investment Securities) at fair value in connection to the sale of a 60% 

25

ICU MEDICAL, INC. AND SUBSIDIARIESNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Continued)

interest of our IV Solutions business (see Note 4: Assets Held for Sale and Disposal of Business). The fair value was estimated using a market-based approach and is classified as a Level 3 fair value measurement. 

Note 11:  Investment Securities

Investments in Non-Marketable Equity SecuritiesInvestments in Unconsolidated AffiliatesWe hold equity method investments in certain entities. We apply the equity method of accounting for investments in unconsolidated affiliates when we determine we have a significant influence, but not a controlling interest in the investee. We determine whether we have significant influence by considering key factors such as ownership interest, representation on the board of directors, participation in policy making decisions, business relationship and material intra-entity transactions, among other factors. Our equity method investments are reported at cost and adjusted each period for our share of